Products

Resolve Analysis Platform1-click analysis Ozette LabHigh-quality data for your trials Managed Cytometry AnalysisOzette Scientists help you with your data
Data Requirements FAQs Pricing

Resources

News Publications Blog Case studies Events

Company

About Careers Compliance
Log in Try Resolve Now
Case studyNature

Computationally-driven analysis aids advancement of cancer drug development.

Ozette’s technology, in conjunction with other new methods, reveals a distinct T-cell population that suppresses immune effectiveness in the tumor microenvironment and helps inform drug development in immuno-oncology.

Summary

Inflammation is a hallmark of the tumor microenvironment and an area of active investigation. To better understand how tumor inflammation differs from general inflammation — such as in gum disease — Drs. Prlic, Mair, and Erikson employed novel methods, including high-parameter flow cytometry and Ozette’s foundational technology, full annotation using shape-constrained trees (FAUST). FAUST is a machine-learning algorithm that discovers and annotates statistically relevant cellular phenotypes in an unsupervised manner. Pairing high-parameter flow cytometry with Ozette’s next-generation analysis helped decipher the complex immune landscape of tumors and revealed tumor-specific cell populations that modulate immune responses.

T cells are known orchestrators of inflammation — driving it, and in the case of T-regulatory cells, damping it, to respond to dynamic environments. FAUST revealed hundreds of distinct cellular phenotypes. In combination with single-cell RNA sequencing data and follow-up functional assays, these findings led Prlic et al. to identify one type of T-regulatory cell — a unique population expressing IL-1R1 and ICOS — that localized to solid tumors and suppressed immune defenses.

The Fred Hutch researchers compared their findings in head-and-neck solid tumors to 21 different cancer types. Transcriptomic data demonstrated that this T-regulatory cell population was present in all 19 solid-tumor cancers, but not in the two blood cancers. The team hypothesizes that targeting this newly identified population may be an effective way to more specifically target solid tumors — especially intriguing because solid tumors have not responded to immunotherapies as well as blood cancers, in part due to a lack of tumor-specific targets. They are now pursuing a bispecific antibody targeting IL-1R1- and ICOS-expressing T-regulatory cells to determine the impact on solid tumors.

All case studies

Get started

See 1-click analysis on your own data

Start a free 7-day trial with 60 files, or talk to an Ozette scientist about your study.

Try it now